Cancer Therapy pp 186-191 | Cite as

Autologous Bone Marrow Transplantation

  • M. Körbling
  • T. M. Fliedner
  • K. Rother
  • M. Wannenmacher
  • W. Hunstein
Conference paper

Abstract

The therapeutic concept of autologous bone marrow blood stem cell-transplantation is based on dose escalation of consolidation treatment into a “supralethal” range. The conditions for that are that the tumor remaining in the patient must respond to “supralethal” dose escalation of pretransplant therapy, and the escalated dose therapy must be primarily myelotoxic, together with acceptable extramedullary toxicity. The therapeutic advantage of the autologous bone marrow transplantation approach is obvious:
  • A marrow donor is not needed

  • The early transplant-related death rate is low due to the lack of “graft-versus-host” disease, due to the low incidence of interstitial pneumonitis, and due to the fact that there is no rejection of the graft.

Keywords

Toxicity Europe Lymphoma Leukemia Interferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barlogie B, Alexanian R, Dicke KA, et al (1987) High dose ehemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869–872PubMedGoogle Scholar
  2. Bensinger WI, Berenson RJ, Andrews RG, et al (1988) Proceedings of XIVth Annual Meeting of the European Cooperative Group for Bone Marrow Transplantation, Chamonix, France, 10–13 April 1988Google Scholar
  3. Chang J, Coutinho L, Morgenstern G, et al (1986) Reconstitution of haemopoietic system with autologous marrow taken during relapse of acute myeloblastic leukaemia and grown in longterm culture. Lancet 1:294–295PubMedCrossRefGoogle Scholar
  4. Fabian I, Bleiberg I, Riklis I, et al (1987) Enhanced reconstitution of hematopoietic organs in irradiated mice following their transplantation with bone marrow cells pretreated with recombinant interleukin 3. Exp Hematol 15:1140–1144PubMedGoogle Scholar
  5. Fefer A (1986) Current status of syngeneic marrow transplantation and its relevance to autografting. Clin Haemtaol 15:49–65Google Scholar
  6. Fliedner TM, Calvo W, Körbling M, et al (1979) Collection, storage and transfusion of blood stem cells for the treatment of hemopoietic failure. Blood Cells 5:313–328PubMedGoogle Scholar
  7. Hagenbeck A, Martens CM (1987) Conditioning regimens before bone marrow transplantation in acute myelocytic leukemia. In: Dicke KA, Spitzer G, Jagannath S (eds) Autologous bone marrow transplantation. Proceedings of the third international symposium. University of Texas MD. Anderson Hospital and Tumor Institute, Houston, pp 99–103Google Scholar
  8. Hess AD, Horwitz L, Beschomer WE, Santos GW (1985) Development of graft-versus-host disease like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. J Exp Med 161:718–730PubMedCrossRefGoogle Scholar
  9. Jagannath S, Dicke KA, Armitage JO, et al (1986) High dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med 104:163–168PubMedGoogle Scholar
  10. Kersey HJ, Weisdorf D, Nesbit ME, et al (1987) Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 317:461–467PubMedCrossRefGoogle Scholar
  11. Körbling M, Hess AD, Tutschka PJ, et al (1982) 4-Hydroperoxycyclophosphamide: a model for eliminating residual human tumour cells and T-lymphocytes from the bone marrow graft. Br J Haematol 52:89–96PubMedCrossRefGoogle Scholar
  12. Körbling M, Dörken B, Ho AD, et al (1986) Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood 67:529PubMedGoogle Scholar
  13. Richman CM, Weiner RS, Yankee RA, et al (1976) Increase in circulating stem cells following chemotherapy in man. Blood 47:1031–1034PubMedGoogle Scholar
  14. Santos GW, Tutschka PJ, Brookmeyer R, et al (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347–1353PubMedCrossRefGoogle Scholar
  15. Sharkis SJ, Santos GW, Colvin M (1980) Elimination of acute myelogenous leukemic cells from marrow and tumor suspensions in the rat with 4-hydroperoxyclophosphamide. Blood 55:521–523PubMedGoogle Scholar
  16. Yeager AM, Kaizer H, Santos GW, et al (1985) Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315:141–147CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • M. Körbling
  • T. M. Fliedner
  • K. Rother
  • M. Wannenmacher
  • W. Hunstein

There are no affiliations available

Personalised recommendations